Article Per Year (5 Year)
p-Index From 2021 - 2026
1.116
P-Index
This Author published in this journals
All Journal JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA PengabdianMu: Jurnal Ilmiah Pengabdian kepada Masyarakat Borneo Journal Of Pharmascientech Jurnal Sains dan Kesehatan
Yusuf, Helmy
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Public Health Social Sciences Other

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Borneo Journal Of Pharmascientech

 1 
Studi in silico tentang naringin sebagai reseptor anti-HER-2 dalam pengobatan kanker payudara Abdurrahman, Abdurrahman; Rijal, Muh. Agus Syamsur; Yusuf, Helmy; Norhayati; Rizaldi, Gusti
BORNEO JOURNAL OF PHARMASCIENTECH Vol 8 No 2 (2024): Borneo Journal of Pharmascientech
Publisher : Universitas Borneo Lestari

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51817/bjp.v8i2.535

Abstract

Overexpression of Human Epidermal Receptor-2 (HER-2) is the cause of the development of breast cancer, so HER-2 can be a target for anticancer therapy. Trastuzumab is the drug of choice in inhibiting the HER-2 receptor and tyrosine kinase, but the weakness of this drug is that drug resistance can occur. Naringin has potential as a breast cancer therapy. The research aims to determine the inhibiting overexpression of the HER-2 receptor by naringin using in silico method. Molecular docking has been carried out by optimizing naringin and trastuzumab, preparing the HER-2 protein target (PDB ID 3PP0), validating the molecular docking protocol, and docking naringin and trastuzumab on HER-2. The research produced a binding energy of -8,66 kcal/mol, while the binding energies of the original ligand and trastuzumab to HER-2 were -9,94 kcal/mol and -5,87 kcal/mol, respectively. The binding energy shows that naringin has potential as an anti-breast cancer agent as indicated by its stronger affinity for HER2.
Co-Authors Abdurahman Abdurrahman ACHMAD FUAD Amilia, Alya Nur Anang Setyo Wiyono Aty Widyawaruyanti Aulia, Nanda Intan Bambang Tri Purwanto Dewi Isadiartuti Dini Retnowati Diyah, Nuzul Wahyuning Esti Hendradi Hadi Poerwono Handayani, Rosita Hariyadi, Dewi Melany Ida Kristianingsih Idha Kusumawati Juni Ekowati Marcellino Rudyanto Maulia, Arwinda Melanny Ika Sulistyowaty Muhammad Agus Syamsur Rijal Munandar, Tristiana Erawati Ninis Yuliati, Ninis Noorma Rosita Norhayati Purnomo, Ahmad Toto Purwitasari, Neny Rahman, Ave Ramadhani, Firmansyah Ardian Retno Widyowati Rizaldi, Gusti Savitri, Orchidea Meidy Nurintan Siswandono, Siswandono Sudjarwo Sudjarwo Sukardiman Tri Widiandani Tutik Sri Wahyuni